Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives

References

• Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005;3:21
   PubMed Web of Science ®Google Scholar
• Dunayevich E, Ascher-Svanum H, Zhao F, et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry 2007;68:1163-71
   PubMed Web of Science ®Google Scholar
• Matza L, Phillips GA, Revicki D, et al. Developing a clinician-reported measure of reasons for antipsychotic discontinuation or continuation in the treatment of schizophrenia. Presented at CINP, Chicago, IL, July 9–13, 2006
   Google Scholar
• Matza LS, Phillips G, Revicki DA, et al. Developing a patient interview to assess reasons for antipsychotic discontinuation or continuation in the treatment of schizophrenia [abstract]. Schizophr Bull 2007;33:595
   Web of Science ®Google Scholar
• Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacol 2009;35:581-90
   Web of Science ®Google Scholar
• Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812
   Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised (Publication ADM 76-338). Rockville, MD: US Dept of Health, Education, and Welfare, 1976:218-22
   Google Scholar
• Faries D, Ascher-Svanum H, Nyhuis A, et al. The validation of a measure assessing reasons for antipsychotic discontinuation and continuation from patient's and clinician's perspectives. Presented at the 15th Biennial Winter Workshop in Psychoses, Barcelona, Spain, November 15–18, 2009
   Google Scholar
• Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophrenia Research 2005;79:231-8
   PubMed Web of Science ®Google Scholar
• Perkins DO, Gu H, Weiden PJ, et al. Comparison of Atypicals in First Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69:106-13
   PubMed Web of Science ®Google Scholar
• Perkins DO, Johnson JL, Hamer RM. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 2006;83:53-63
   PubMed Web of Science ®Google Scholar
• Rossi A, Vita A, Tiradritti P, et al. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol 2008;23:216-22
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Chang S, Choe Y, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000;61:382-6
   PubMed Web of Science ®Google Scholar
• Loffler W, Kilian R, Toumi M, et al. Schizophrenic patients’ subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003;36:105-12
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64(Suppl. 16):10-13
   PubMed Web of Science ®Google Scholar
• Mutsatsa SH, Joyce EM, Hutton SB, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand 2003;108:439-46
   PubMed Web of Science ®Google Scholar
• Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-83
   PubMed Web of Science ®Google Scholar
• Awad GA. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993;19:609-18
   PubMed Web of Science ®Google Scholar
• Hofer A, Rettenbacher MA, Edlinger M, et al. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. Acta Psychiatr Scand 2007;116:354-61
   PubMed Web of Science ®Google Scholar
• Mohamed S, Rosenheck R, McEvoy J, et al. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull 2009;35:336-46
   PubMed Web of Science ®Google Scholar
• Schennach-Wolff R, Jager M, Seemuller F, et al. Attitude towards adherence in patients with schizophrenia at discharge. J Psychiatr Res 2009;43:1294-301
   PubMed Web of Science ®Google Scholar
• Lambert M, Conus P, Eide P, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004;19:415-22
   PubMed Web of Science ®Google Scholar
• Naber D. Subjective effects of antipsychotic drugs and their relevance for compliance and remission. Epidemiol Psichiatr Soc 2008;17:174-6
   PubMed Web of Science ®Google Scholar
• Karow A, Czekalla J, Dittmann RW, et al. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 2007;68:75-80
   PubMed Web of Science ®Google Scholar
• de Millas W, Lambert M, Naber D. The impact of subjective well-being under neuroleptic treatment on compliance and remission. Dialogues Clin Neurosci 2006;8:131-6
   PubMedGoogle Scholar
• Voruganti LN, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 2002;56:37-46
   PubMed Web of Science ®Google Scholar